BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion
This article was originally published in PharmAsia News
Executive Summary
Bristol-Myers Squibb and Japanese partner Otsuka Pharmaceuticals have entered into a two-part deal that extends their 10-year-old collaboration to sell the blockbuster psychiatric drug Abilify (aripiprazole) in the U.S. and also gives Otsuka a presence in oncology in the U.S., Europe and Japan
You may also be interested in...
Otsuka Searches For Value In Portfolio Through Patient Compliance Technology
Alliance with Lundbeck emphasizes search for innovation in all corners of CNS research.
Novartis Edges Out BMS In Japan With First-line Indication Approval For Tasigna Ahead Of Sprycel
TOKYO - The showdown between Novartis' Tasigna (nilotinib) and Bristol-Myer Squibb's Sprycel (dasatinib) for share of the chronic myeloid leukemia market has escalated in Japan as Tasigna received approval from Japan's Ministry of Health, Labor and Welfare Dec. 21 for first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia
Novartis Edges Out BMS In Japan With First-line Indication Approval For Tasigna Ahead Of Sprycel
TOKYO - The showdown between Novartis' Tasigna (nilotinib) and Bristol-Myer Squibb's Sprycel (dasatinib) for share of the chronic myeloid leukemia market has escalated in Japan as Tasigna received approval from Japan's Ministry of Health, Labor and Welfare Dec. 21 for first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia